tivoxavir marboxil (TRX100)
/ Traws Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
February 07, 2026
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
(clinicaltrials.gov)
- P2 | N=105 | Active, not recruiting | Sponsor: Traws Pharma, Inc. | Trial completion date: Jun 2026 ➔ Jan 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026 | Withdrawn ➔ Active, not recruiting
Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases
January 29, 2026
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Traws Pharma, Inc.
New P2 trial • Infectious Disease • Influenza • Respiratory Diseases
January 22, 2026
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=66 | Completed | Sponsor: Traws Pharma, Inc. | Recruiting ➔ Completed | N=32 ➔ 66
Enrollment change • Trial completion
January 13, 2026
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy...
(The Manila Times)
IND • Influenza
April 11, 2025
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation (with optional food effect) Study of Orally Administered TRX-100 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of TRX-100 in Healthy Volunteers
(ANZCTR)
- P1 | N=40 | Completed | Sponsor: Trawsfynydd Therapeutics AU Pty Ltd (on behalf of Traws Pharma, Inc.) | Recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
January 04, 2025
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Traws Pharma, Inc.
New P1 trial
November 23, 2024
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation (with optional food effect) Study of Orally Administered TRX-100 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of TRX-100 in Healthy Volunteers
(ANZCTR)
- P1 | N=40 | Recruiting | Sponsor: Trawsfynydd Therapeutics AU Pty Ltd (on behalf of Traws Pharma, Inc.) | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2024
Enrollment open • Trial initiation date • Infectious Disease • Influenza • Respiratory Diseases
1 to 7
Of
7
Go to page
1